Assessing cost-effectiveness in the management of multiple sclerosis.
about
Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.Multiple sclerosis: relapses, resource use, and costs.The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
P2860
Assessing cost-effectiveness in the management of multiple sclerosis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Assessing cost-effectiveness in the management of multiple sclerosis.
@ast
Assessing cost-effectiveness in the management of multiple sclerosis.
@en
type
label
Assessing cost-effectiveness in the management of multiple sclerosis.
@ast
Assessing cost-effectiveness in the management of multiple sclerosis.
@en
prefLabel
Assessing cost-effectiveness in the management of multiple sclerosis.
@ast
Assessing cost-effectiveness in the management of multiple sclerosis.
@en
P2860
P356
P1476
Assessing cost-effectiveness in the management of multiple sclerosis.
@en
P2093
Ceri J Phillips
Ioan Humphreys
P2860
P356
10.2147/CEOR.S4225
P407
P577
2009-11-18T00:00:00Z